Literature DB >> 26592193

Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD.

Henry Lik-Yuen Chan1, Philip Kam-Tao Li2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26592193     DOI： 10.1038/nrneph.2015.189

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.

Authors: 
Journal:  Kidney Int Suppl       Date:  2008-04       Impact factor: 10.545

Review 2.  Hepatitis C.

Authors:  Daniel P Webster; Paul Klenerman; Geoffrey M Dusheiko
Journal:  Lancet       Date:  2015-02-14       Impact factor: 79.321

Review 3.  Infectious complications in dialysis--epidemiology and outcomes.

Authors:  Philip Kam-Tao Li; Kai Ming Chow
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

4.  Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.

Authors:  F Fabrizi; V Dixit; P Messa; P Martin
Journal:  J Viral Hepat       Date:  2014-07-16       Impact factor: 3.728

5.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

Review 6.  Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?

Authors:  F Fabrizi; V Dixit; P Messa
Journal:  J Viral Hepat       Date:  2012-07-17       Impact factor: 3.728

7.  Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Authors:  Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton
Journal:  Ann Intern Med       Date:  2015-07-07       Impact factor: 51.598

8.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Authors:  David Roth; David R Nelson; Annette Bruchfeld; AnnMarie Liapakis; Marcelo Silva; Howard Monsour; Paul Martin; Stanislas Pol; Maria-Carlota Londoño; Tarek Hassanein; Philippe J Zamor; Eli Zuckerman; Shuyan Wan; Beth Jackson; Bach-Yen Nguyen; Michael Robertson; Eliav Barr; Janice Wahl; Wayne Greaves
Journal:  Lancet       Date:  2015-10-05       Impact factor: 202.731
  8 in total
  1 in total

Review 1.  Hepatitis C Virus Infection in Chronic Kidney Disease.

Authors:  Marco Ladino; Fernando Pedraza; David Roth
Journal:  J Am Soc Nephrol       Date:  2016-04-19       Impact factor: 10.121
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.